Scarica l'app Stockscreener
1.86
1.59%
-0.03
Genprex Inc Borsa (GNPX) Ultime notizie
Genprex reports potential compliance with Nasdaq equity listing rule By Investing.com - Investing.com Canada
Genprex (GNPX) awards 28,500 RSUs to Chief Medical Officer under 2018 plan - Stock Titan
Genprex (GNPX) CEO Ryan Confer reports 45,000 RSUs award - Stock Titan
Genprex (GNPX) grants director 9,000 RSUs after reverse stock split - Stock Titan
Genprex reports potential compliance with Nasdaq equity listing rule - Investing.com
Genprex (GNPX) Stock Analysis Report | Financials & Insights - Benzinga
Street Watch: Will Genprex Inc stock split attract more investorsMarket Trend Review & Real-Time Stock Movement Alerts - moha.gov.vn
How Genprex Inc. stock reacts to inflationary pressuresWeekly Gains Summary & Safe Entry Momentum Stock Tips - Bölüm Sonu Canavarı
MSN Money - MSN
Aug Catalysts: How Genprex Inc. stock reacts to inflationary pressuresQuarterly Profit Review & Verified Chart Pattern Signals - moha.gov.vn
Can Genprex Inc. stock beat market expectations this quarterJuly 2025 Price Swings & Consistent Income Trade Recommendations - Улправда
What catalysts could drive Genprex Inc. stock higherJuly 2025 Setups & Long-Term Capital Growth Strategies - Улправда
How Genprex Inc. stock performs in high volatility marketsInflation Watch & Free Real-Time Market Sentiment Alerts - Улправда
Momentum Shift: Why Genprex Inc stock remains on buy listsEarnings Risk Summary & Fast Moving Stock Watchlists - moha.gov.vn
Will Genprex Inc. (2DE0) stock benefit from mergers2025 Performance Recap & Long-Term Investment Growth Plans - Улправда
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Dividend Watch: Can Genprex Inc. stock beat market expectations this quarterPortfolio Update Report & Technical Confirmation Trade Alerts - Улправда
Why analysts upgrade Genprex Inc. stock2025 Buyback Activity & Fast Moving Stock Watchlists - DonanımHaber
Will Genprex Inc. stock sustain high P E ratios2025 Breakouts & Breakdowns & AI Enhanced Trading Alerts - DonanımHaber
How Genprex Inc. (2DE0) stock reacts to new regulationsQuarterly Portfolio Report & AI Based Trade Execution Alerts - Улправда
Why Genprex Inc. stock is rated strong buyJuly 2025 Final Week & Community Consensus Trade Signals - DonanımHaber
Is Genprex Inc. stock a smart buy before Fed meetingQuarterly Profit Report & Accurate Buy Signal Notifications - DonanımHaber
Genprex Secures U.S. Patent for Reqorsa® Therapy - MSN
Genprex Inc Stock Analysis and ForecastSector-Based Investing & High Yield Market Growth - earlytimes.in
Will Genprex Inc. (2DE0) stock recover faster than industry2025 Analyst Calls & Risk Managed Investment Signals - Newser
Is Genprex Inc. (2DE0) stock undervalued after correctionJuly 2025 PreEarnings & Risk Controlled Daily Trade Plans - Newser
Is Genprex Inc. stock cheap at current valuationWeekly Profit Report & Community Driven Trade Alerts - Newser
Congressman Buys Shares Of Small Cap Lift Truck Company You've Probably Never Heard Of - Benzinga
Can Genprex Inc. (2DE0) stock reach $200 price targetEarnings Growth Summary & Entry and Exit Point Strategies - Newser
Get in on Genprex Inc’s (GNPX) buy-in window today! - setenews.com
Rep. Tim Moore Purchases Shares of Genprex (NASDAQ:GNPX) - Defense World
Why Genprex Inc. stock remains on buy listsWeekly Profit Summary & Fast Gaining Stock Reports - Newser
Genprex, Inc. Stock (GNPX) Opinions on Recent Preclinical Data Release - Quiver Quantitative
Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules - Aktiellt
Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules - Aktiellt
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire) - Aktiellt
Taking the lead: Genprex Inc (GNPX) - Setenews
Genprex regains Nasdaq bid price compliance, receives equity extension By Investing.com - Investing.com Australia
Genprex regains Nasdaq bid price compliance, receives equity extension - Investing.com
Genprex keeps Nasdaq listing with bid-price fix, equity waiver granted - Stock Titan
Genprex reports phase 1 data for lung cancer gene therapy By Investing.com - Investing.com Nigeria
Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Tria - GuruFocus
Genprex (GNPX) Shares Positive Acclaim-1 Trial Data for Lung Can - GuruFocus
Genprex reports phase 1 data for lung cancer gene therapy - Investing.com
Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer - PR Newswire
Genprex files prospectus supplement for up to $75 million at-the-market offering By Investing.com - Investing.com Australia
Genprex files prospectus supplement for up to $75 million at-the-market offering - Investing.com Australia
Genprex Inc. (GNPX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
0.36%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):